


ADVANCED PROTEOME THERAPEUTICS (APC.V)

Investor Presentation

Dr. Allen Krantz
President, CEO and Founder

November, 2016



Advanced Proteome
Therapeutics Inc.

Forward Looking Statements

Certain written and oral statements included in this presentation may constitute “forward-looking information” which reflect the current expectations of Advanced Proteome Inc. This information reflects Advanced Proteome’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking information involves significant known and unknown risks, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking information. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking information contained in this presentation. Although forward-looking information contained in this presentation is based upon what Advanced Proteome believes to be reasonable assumptions, management cannot assure investors that actual results, performance or achievements will be consistent with this forward-looking information and cautions that undue reliance should not be placed on the forward-looking information. The forward-looking information is made as of the date of this presentation and Advanced Proteome does not assume any obligation to update or revise it to reflect new events or circumstances, except as required by law.



Advanced Proteome
Therapeutics Inc.

Cancer is Where the Action is.....

20M

USA Cancer Patients

\$38B

US Spend on Cancer Therapies

\$110B

WW Spend on Cancer Therapies

Cancer Deals Lead the Pack

24%
Cancer

13%
Infectious Disease


10%
Neurology

7%
Auto Immune and
Inflammatory

Preponderance of cancer deals are signed during the discovery or pre-clinical phases!


40% of adults will be diagnosed with cancer in their lifetimes!

Cancer Treatment is Evolving...



A new generation of cancer therapy: ADC targeted therapy

Current Standard of Care - Chemotherapy



Chemo Drug




Cancer Cells

Toxic chemo drug affects both cancer cells and healthy cells

- Very high morbidity
- Kills cancer and healthy cells
- Resistance develops

Advancement in Treatment— ADC Targeted Therapy



- Targets and **selectively** destroys cancer cells
- Durable responses
- Reduced Morbidity

Allows drug to be **delivered** directly to specific cancer cells, reducing toxicity

Antibody Drug Conjugates: The Challenge

Major Problems Today

Antibody-Drug Ratio

- Marketed ADC's are grossly impure
- Very difficult to control and reproduce mixtures
- Difficulties separating preferred ADC from suboptimal Ab forms in mixture

- 1) Toxicities have resulted post-market
- 2) Each batch produces a mixture of ratios
- 3) High manufacturing costs

Advanced Proteome's Vision


Site-specific labeling
of antibodies

Create pure &
homogeneous product


- 1) Easier to manufacture
- 2) Cheaper to manufacture
- 3) Lower toxicity than chemo

APC's Focus – Site Specific Labeling of Proteins

Annexin Protein Conjugate



Human Serum Albumin Conjugate



APC has developed unique site-specific methods for labeling proteins

APC's Site Specific Labeling Approach

Universal Antibody Connector

- Connect to a universal site on target antibody
- Link chemo to connector at universal site



Toxic chemo drug delivered to cancer cells via antibodies



Cancer cell destruction can stimulate the patients' immune system

Develop capabilities to attach any payload to any such antibody

Our Two Paths to Growth

Licensing

Partners determine target + APC linker technology



Validation of APC technology

Licensing of APC technology to partner for specific target

Product Development

Antibody optioned from UofT + APC linker technology



Validation of antibody and APC technology combination

License proprietary molecule to pharmaceutical companies for further development

Over the Next 12 months...

- 
- 1) Further establish partnerships for development of cancer therapeutics
 - 2) Execute existing partnership projects to further validate our technology
 - 3) Build on partnerships to create licensing and potential revenue stream opportunities
 - 4) Develop our own proprietary molecular assets in partnership with University of Toronto

Representative Drug Conjugate Investments

Company	Biotech Partner	Date	Potential Worth (mm)
Roche	Catalent	January 2016	\$618
Tekeda	Immunogen	March 2015	\$440
Genmab	Seattle Genetics	September 2014	\$211
Merck	Endocyte	April 2012	\$1,000
Abbott Laboratories	Seattle Genetics	March 2012	\$208
Endo Pharmaceuticals	Mersana	March 2012	\$270
Eli Lilly	ImmunoGen	December 11 2012	\$200/Drug
Pfizer	Seattle Genetics	January 2011	\$208
Novartis	ImmunoGen	October 2010	\$200/Drug
Genentech	Seattle Genetics	August 2010	\$912
Millenium	Seattle Genetics	December 2009	\$290
GlaxoSmithKline	Seattle Genetics	December 2009	\$402
Amgen	ImmunoGen	September 2009	\$35

Why Invest?

Platform technology with ability to be licensed and developed into proprietary products for APC

Partnerships could lead to earlier licensing and revenue stream opportunities

Potential near-term acquisition target

Capital Structure

Ticker (TSX-V)	APC
Shares Outstanding	112.88M
Stock Price (11/03/16)	\$0.08
Market Capitalization (11/03/16)	\$9.48M
Options (Avg. \$0.13)	8.02M
Fully Diluted Shares Outstanding	120.9M
Cash (04/30/16)	\$92.58K
Debt	\$151k
Year End	July 31st

Management Team

Dr. Allen Krantz
Chief Executive Officer,
Director and Founder

Dr. Krantz obtained his Masters and Ph.D degrees from Yale University. From 1968 to 1980, Mr. Krantz was a member of the Faculty of Chemistry at Stony Brook University, holding appointments in both the Department of Chemistry and the Department of Pharmacological Sciences. Formerly, Mr. Krantz has served as Vice President of Research at Syntex Research Canada and Executive Vice President at RedCell Inc.

Kenneth Phillippe
Chief Financial Officer

Mr. Phillippe is a Chartered Accountant with over 25 years' experience working with public companies. Mr. Phillippe obtained a B.Comm degree from the University of British Columbia in 1976. His former roles include Chair of the Audit Committee of Urodynamix Technologies Ltd., CFO of Columbia Goldfields, and CFO of both Exchequer Resource Corp. and Secretary of Bold Ventures Inc.

Ella Korets-Smith
MSc, MBA
Business Development

Ella is a business development and marketing professional with experience in the biotechnology, pharma and medical device industries. She has a track record of closing deals and leading successful marketing and business development programs. Her extensive and growing network of business leaders extends her reach to customers and partners in all key markets in North America and around the world. Ella has an MSc in Medical Genetics from the University of Toronto and an MBA from Dalhousie University.

Board of Directors

Dr. Allen Krantz

Chief Executive Officer, Director
and Founder

Dr. Krantz obtained his Masters and Ph.D degrees from Yale University. From 1968 to 1980, Mr. Krantz was a member of the Faculty of Chemistry at Stony Brook University, holding appointments in both the Department of Chemistry and the Department of Pharmacological Sciences. Formerly, Mr. Krantz has served as Vice President of Research at Syntex Research Canada and Executive Vice President at RedCell Inc.

Dr. Randal Chase

Director

Dr. Chase has over 40 years of experience in biotechnology and related fields. Dr. Chase began his career at Bristol Meyers and Glaxo Canada Inc., where he held the positions of Director and Senior Vice President, respectively. He is the former President of several companies including Quadra Logic Technologies Inc., North American Vaccine and Sanofi Pasteur Canada. Dr. Chase has served as President and CEO of ImmunoVaccine Technologies. Dr. Chase was the President and CEO of Shire Biologics, as well as Chairman of the Board of Directors of Medicago.

Dr. Gary Hayes

Director

Dr. Hayes graduated from the University of Manitoba in 1978. He has 27 years in clinical Family Practice, and has been a medical advisor for numerous companies and sports teams that utilize his extensive knowledge of therapeutics. Dr. Hayes has also been active as a Director of several publically listed companies.

Jean Bellin

Director

Jean Bellin has more than 25 years' experience in the pharmaceutical industry. He began his career with 12 years at Eli Lilly & Company, holding positions in sales, marketing and general management in Brazil, the US, the Scandinavian countries, and Italy. He then founded and served as Managing Director of Dupont Pharma Italy. In 1993, Mr. Bellin became head of the international division of UCB, a \$2 billion publically traded, biopharmaceutical group based in Brussels, Belgium. Mr. Bellin received his Bachelors degree in Economic, Political and Social Sciences from the Universitaries Saint Louis in Brussels and a license in applied economic sciences from Catholique de Louvain in Belgium.

ADVANCED PROTEOME THERAPEUTICS (APC.V)



Advanced Proteome
Therapeutics Inc.